VSTM Verastem Oncology Doses First Patient in TARGET-D 202 Phase 2 Registration-Directed Trial of VS-7375 for KRAS G12D-Mutated Advanced Non
VSTM Verastem Oncology Doses First Patient in TARGET-D 202 Phase 2 Registration-Directed Trial of VS-7375 for KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer
Story updates
08:01:41 PM UTC
SquawkNews
VSTM Verastem Oncology doses first patient in target-d 202 phase 2 registration-directed trial of vs-7375 for kras g12d-mutated advanced non-small cell lung cancer
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.